Hypothesis

If retinal mitochondrial function determines the responsiveness of intrinsically photosensitive retinal ganglion cells (ipRGCs) to blue light, then boosting mitochondrial health with a targeted antioxidant will increase ipRGC sensitivity to morning blue‑enriched light, producing larger phase advances and improved sleep metrics without exacerbating evening blue‑violet phototoxicity.

Mechanistic Rationale

ipRGCs rely on melanopsin regeneration and calcium signaling, both energy‑intensive processes that depend on healthy mitochondria【https://www.chronobiologyinmedicine.org/m/journal/view.php?number=167】. Retinal mitochondria are vulnerable to oxidative stress, especially from blue‑violet wavelengths (415‑455 nm) that cause photodamage【https://doi.org/10.1038/s41419-018-0331-5】. When mitochondrial efficiency declines, opsin recycling slows, reducing photon capture and weakening melatonin suppression signals to the suprachiasmatic nucleus. Conversely, enhancing mitochondrial resilience should preserve opsin turnover, heighten ipRGC firing, and strengthen circadian entrainment pathways.

Recent work shows that melatonin suppression alone does not predict sleep improvement from evening blue‑blockers【https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1699303/full】, suggesting variability in ipRGC sensitivity drives inconsistent outcomes. Moreover, morning bright blue‑enriched light advances phase, lengthens sleep, and amplifies melatonin rhythms【https://journal.psych.ac.cn/xlkxjz/EN/Y2023/V31/I9/1698】. Linking mitochondrial health to this response offers a mechanistic explanation for individual differences and a potential lever to amplify benefits.

Testable Predictions

1. Participants receiving MitoQ (a mitochondria‑targeted antioxidant) will exhibit greater melatonin suppression in response to a standardized 30‑minute, 1000 lx blue‑enriched light pulse (5000 K) compared with placebo.
2. The same MitoQ group will show larger advances in dim‑light melatonin onset (DLMO) after a week of morning blue‑light exposure (1000‑6000 lx, 30 min) than controls.
3. Sleep actigraphy and polysomnography will reveal increased total sleep time, reduced sleep latency, and enhanced slow‑wave activity in the MitoQ condition relative to placebo.
4. Evening exposure to low‑intensity blue‑violet light (415‑455 nm, <1 lx) will not produce significantly more retinal oxidative stress biomarkers (e.g., 8‑OH‑dG) in the MitoQ group than in controls, indicating that enhanced ipRGC sensitivity does not increase phototoxic risk.

Experimental Design

• Design: Double‑blind, placebo‑controlled, crossover trial with a 2‑week washout.
• Participants: 60 healthy adults aged 20‑35, stratified by baseline macular pigment optical density (MPOD) to control for pre‑existing retinal antioxidant capacity.
• Intervention: MitoQ 10 mg daily vs. matching placebo for 14 days.
• Procedures:
  • Day 0: Baseline DLMO, actigraphy, polysomnography (night 1), and retinal oxidative stress blood draw.
  • Days 1‑7: Morning blue‑light exposure (30 min, 1000 lx, 5000 K) upon waking; evening dim (<10 lx, 2700 K) conditions.
  • Day 8: Repeat DLMO, actigraphy, polysomnography (night 2), and oxidative stress assay.
  • After washout, repeat with opposite supplement.
• Outcomes: Primary – change in DLMO (phase advance). Secondary – melatonin suppression magnitude, sleep efficiency, slow‑wave power, retinal oxidative stress markers.

Potential Outcomes and Falsifiability

If MitoQ does not produce greater melatonin suppression, larger phase advances, or improved sleep metrics relative to placebo, the hypothesis that mitochondrial health limits ipRGC sensitivity is falsified. Conversely, a significant improvement in the primary and secondary outcomes, without elevated evening oxidative stress, would support the mechanistic link and suggest that mitochondrial augmentation could personalize circadian light therapy.

This framework directly extends the existing evidence: it acknowledges the precise circadian potency of blue light【https://www.chronobiologyinmedicine.org/m/journal/view.php?number=167】, addresses the lack of universal benefit from blue‑blockers【https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2025.1699303/full】, and proposes a biologically plausible modifier—retinal mitochondrial function—that can be measured and manipulated.